PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN

Contrast Media and Molecular Imaging

Volumn 9, Issue 5, 2014, Pages 342-348

  Pan, Donghui ^a   Yan, Yongjun ^b   Yang, Ronghua ^c   Xu, Yu Ping ^a   Chen, Fei ^a   Wang, Lizhen ^a   Luo, Shineng ^a   Yang, Min ^a  

^a BEIJING HOSPITAL   (China)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

18F; Bombesin; Fluoride aluminum chelate; PET; Prostate cancer

Indexed keywords

ALUMINUM; BOMBESIN DERIVATIVE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GASTRIN RELEASING PEPTIDE RECEPTOR; OCTANOL; PHOSPHATE BUFFERED SALINE; RADIOPHARMACEUTICAL AGENT; WATER; 1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; BOMBESIN; FLUORINE; HETEROCYCLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CLINICAL EVALUATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC50; IMAGE ANALYSIS; IMAGE QUALITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; MUSCLE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE TUMOR; RADIOACTIVITY; RADIOCHEMISTRY; RADIOISOTOPE DISTRIBUTION; TUMOR XENOGRAFT; URINARY EXCRETION; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; PATHOLOGY; RADIOGRAPHY; TUMOR CELL LINE;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; FLUORINE RADIOISOTOPES; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 84908009583     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1583     Document Type: Article

References (28)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011, The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236; doi: 10.3322/caac.20121
2. Schroeder RP, van Weerden WM, Krenning EP, Bangma CH, Berndsen S, Grievink-de Ligt CH, et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imag 2011; 38: 1257-1266; doi: 10.1007/s00259-011-1775-3
3. Mari Aparici C, Seo Y. Functional imaging for prostate cancer: therapeutic implications. Semin Nucl Med 2012; 42: 328-342; doi: 10.1053/j.semnuclmed.2012.04.004
4. Lütje S, Boerman OC, van Rij CM, Sedelaar M, Helfrich W, Oyen WJ, Mulders PF. Prospects in radionuclide imaging of prostate cancer. Prostate 2012; 72: 1262-1272; doi: 10.1002/pros.22462
5. Pinto F, Totaro A, Palermo G, Calarco A, Sacco E, D'Addessi A, Racioppi M, Valentini A, Gui B, Bassi P. Imaging in prostate cancer staging: present role and future perspectives. Urol Int 2012; 88: 125-136; doi: 10.1159/000335205.
6. Zaheer A, Cho SY, Pomper MG. New agents and techniques for imaging prostate cancer. J Nucl Med 2009; 50: 1387-1390; doi: 10.2967/jnumed.109.061838
7. Hong H, Zhang Y, Sun JT, Cai WB. Positron emission tomography imaging of prostate cancer. Amino Acids 2010; 39: 11-27; doi: 10.1007/s00726-009-0394-9
8. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med 2011; 5: 81-89; doi: 10.2967/jnumed.110.077941
9. Picchio M, Piert M. Prostate cancer imaging. Eur J Nucl Med Mol Imag 2013; (suppl 1): 1-4; doi: 10.1007/s00259-013-2444-5.
10. Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. Am J Roentgenol 2012; 199: 278-291; doi:10.2214/AJR.12.8816
11. Dijkgraaf I, Franssen GM, McBride WJ, D'Souza CA, Laverman P, Smith CJ, Goldenberg DM, Oyen WJ, Boerman OC. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. J Nucl Med 2012; 53: 947-952; doi: 10.2967/jnumed.111.100891
12. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med 2011; 52(suppl 2): 42S-55S; doi: 10.2967/jnumed.110.085753
13. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999; 59: 1152-1159.
14. Shi J, Jia B, Liu Z, Yang Z, Yu Z, Chen K, Chen X, Liu S, Wang F. 99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer. Bioconjug Chem 2008; 19: 1170-1178; doi: 10.1021/bc700471z
15. Hoffman TJ, Gali H, Smith CJ, Sieckman GL, Hayes DL, Owen NK, Volkert WA. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 2003; 44: 823-831.
16. Fournier P, Dumulon-Perreault V, Ait-Mohand S, Langlois R, Bénard F, Lecomte R, Guérin B. Comparative study of 64Cu/NOTA-[D-Tyr6, βAla11, Thi13, Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging. EJNMMI Res 2012; 2: 8; doi: 10.1186/2191-219X-2-8
17. Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC, Xing L, Chen X. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 2006; 47: 492-501.
18. Honer M, Mu L, Stellfeld T, Graham K, Martic M, Fischer CR, Lehmann L, Schubiger PA, Ametamey SM, Dinkelborg L, Srinivasan A, Borkowski S. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med 2011; 52: 270-278; doi: 10.2967/jnumed.110.081620
19. Yan Y, Chen K, Yang M, Sun X, Liu S, Chen X. A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids 2011; 41: 439-447; doi: 10.1007/s00726-010-0762-5
20. Liu Z, Yan Y, Chin FT, Wang F, Chen X. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem 2012; 18: 11079-11087; doi: 10.1021/jm801285t
21. McBride WJ, Sharkey RM, Karacay H, D'Souza CA, Rossi EA, Laverman P, Chang CH, Boerman OC, Goldenberg DM. A novel method of 18F radiolabeling for PET. J Nucl Med 2009; 50: 991-998; doi: 10.2967/jnumed.108.060418
22. Liu S, Liu H, Jiang H, Xu Y, Zhang H, Cheng Z. One-step radiosynthesis of 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging. Eur J Nucl Med Mol Imag 2011; 38: 1732-1741; doi: 10.1007/s00259-011-1847-4
23. Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ, Goldenberg DM, Boerman OC. A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med 2010; 51: 454-561; doi: 10.2967/jnumed.109.066902
24. Yang M, Gao H, Zhou Y, Ma Y, Quan Q, Lang L, Chen K, Niu G, Yan Y, Chen X. 18F-labeled GRPR agonistsand antagonists: a comparative study in prostate cancer imaging. Theranostics 2011; 1: 220-229.
25. Graham MM, Menda Y. Radiopeptide imaging and therapy in the United States. J Nucl Med 2011; 52(suppl 2): 56S-63S; doi: 10.2967/jnumed.110.085746
26. Liu Z, Niu G, Wang F, Chen X, (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imag 2009; 36: 1483-1494; doi: 10.1007/s00259-009-1123-z
27. Parry JJ, Kelly TS, Andrews R, Rogers BE. In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem 2007; 18: 1110-1117.
28. Abd-Elgaliel WR, Gallazzi F, Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Hoffman TJ, Lever SZ. Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjug Chem 2008; 19: 2040-2048; doi: 10.1021/bc800290c